Table 2.

Adverse events: Listed below are adverse events reported in at least 10% of the patients (n = 119) with advanced solid tumors who received entrectinib on either phase I trial (ALKA-372-001 or STARTRK-1) and that were deemed by the investigators to be related to study drug

Adverse event, n (%)Grade 1Grade 2Grade 3All grades (n = 119)
Fatigue/asthenia28 (24)22 (19)5 (4)55 (46)
Dysgeusia47 (40)3 (3)050 (42)
Paresthesia34 (29)0034 (29)
Nausea29 (24)4 (3)033 (28)
Myalgia23 (19)4 (3)027 (23)
Diarrhea19 (16)3 (3)1 (1)23 (19)
Vomiting19 (16)1 (1)020 (17)
Arthralgia12 (10)6 (5)1 (1)19 (16)
Dizziness14 (12)5 (4)019 (16)
Constipation12 (10)2 (2)014 (12)
Weight increase4 (3)6 (5)2 (2)12 (10)
  • NOTE: There was only one Grade 4 treatment-related adverse event: eosinophilic myocarditis on STARTRK-1. No treatment-related Grade 5 events were reported.